Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
Price : $35 *
At a glance
- Drugs Vonapanitase (Primary)
- Indications Vascular disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Proteon Therapeutics
- 22 May 2015 According to a Proteon Therapeutics media release, 3-year long-term follow-up data from this study will be presented at the 52nd ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) Congress 2015.
- 13 Apr 2015 Results presented at 9th Congress of the Vascular Access Society, as per Proteon Therapeutics.
- 26 Mar 2015 According to a Proteon Therapeutics media release, data from the long-term analysis of this trial was presented at National Kidney Foundation's (NKF) 2015 Spring Clinical Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History